
{
  "Company Overview": {
    "Name": "Kwality Pharmaceuticals Ltd",
    "Sector": "Pharmaceuticals",
    "Industry": "Pharmaceuticals - Indian - Bulk Drugs & Formln",
    "Business Description": "Incorporated in 1983, Kwality Pharma is in the business of manufacturing & trading in Pharmaceuticals & allied products. KPL is an ANVISA and EU GMP certified manufacturer of all pharma products including complex molecules across all dosage forms including niche Biologics. It has a portfolio of 3000+ formulations across 25+ therapeutic areas with categories including generics, cephalosporin, beta-lactam, oncology & biologics. It manufactures and deals in drugs intermediates, chemicals, extracts, alkaloids and other pharmaceutical goods, toilet requisites, medicines, beverages and other medical preparations.",
    "Market Position": "Information not explicitly provided, but peer comparison data suggests a relatively smaller market cap compared to competitors."
  },
  "Financial Metrics": {
    "Market Cap": "₹ 886 Cr.",
    "Current Price": "₹ 854",
    "High/Low": "₹ 961 / ₹ 372",
    "P/E Ratio": 26.0,
    "Book Value": "₹ 232",
    "Dividend Yield": "0.00%",
    "ROCE": "15.9%",
    "ROE": "13.6%",
    "Face Value": "₹ 10.0",
    "Debt-to-Equity Ratio": "Not explicitly provided" 
  },
  "Performance Trends": {
    "Quarterly Results": {
      "Sales": [183.74, 88.19, 64.05, 70.22, 55.81, 56.20, 68.80, 67.45, 69.65, 78.10, 91.98, 80.08, 90.03],
      "Expenses": [100.35, 63.66, 47.82, 52.22, 40.26, 41.10, 57.31, 53.68, 54.42, 61.42, 71.35, 62.74, 70.36],
      "Operating Profit": [83.39, 24.53, 16.23, 18.00, 15.55, 15.10, 11.49, 13.77, 15.23, 16.68, 20.63, 17.34, 19.67],
      "OPM %": [45.38, 27.81, 25.34, 25.63, 27.86, 26.87, 16.70, 20.42, 21.87, 21.36, 22.43, 21.65, 21.85],
      "Other Income": [0.12, 0.84, 1.60, 0.38, 1.13, 0.35, -15.07, 0.40, 0.23, 0.62, -6.52, 0.28, 0.22],
      "Interest": [0.71, 0.50, 1.03, 1.22, 1.18, 1.95, 1.67, 2.19, 2.41, 2.73, 3.06, 2.48, 2.71],
      "Depreciation": [2.66, 3.20, 2.76, 3.14, 3.84, 3.55, 4.43, 4.79, 4.88, 4.82, 5.07, 4.03, 4.62],
      "Profit before tax": [80.14, 21.67, 14.04, 14.02, 11.66, 9.95, -9.68, 7.19, 8.17, 9.75, 5.98, 11.11, 12.56],
      "Tax %": [25.61, 26.77, 25.28, 24.96, 19.47, 28.14, -23.55, 24.90, 23.87, 21.23, 29.26, 24.93, 32.64],
      "Net Profit": [59.62, 15.86, 10.49, 10.53, 9.39, 7.14, -7.40, 5.40, 6.22, 7.68, 4.23, 8.35, 8.46],
      "EPS in Rs": [57.48, 15.29, 10.12, 10.16, 9.08, 6.84, -7.11, 5.22, 6.01, 7.41, 4.20, 8.06, 8.16]
    },
    "Annual Results": {
      "Sales": [60, 52, 74, 98, 137, 166, 139, 262, 456, 251, 307, 340],
      "Expenses": [56, 49, 69, 89, 126, 150, 125, 233, 285, 190, 241, 266],
      "Operating Profit": [4, 3, 5, 9, 12, 16, 14, 29, 172, 61, 66, 74],
      "OPM %": [6, 6, 7, 9, 8, 9, 10, 11, 38, 24, 22, 22],
      "Other Income": [0, 0, 0, 1, 1, 1, 4, 2, 4, -14, -5, -5],
      "Interest": [1, 1, 1, 2, 2, 2, 3, 3, 3, 7, 10, 11],
      "Depreciation": [1, 1, 2, 3, 3, 3, 4, 6, 11, 15, 20, 19],
      "Profit before tax": [2, 1, 2, 6, 7, 11, 11, 21, 162, 26, 31, 39],
      "Tax %": [47, 41, 48, 42, 39, 31, 25, 30, 26, 25, 24, 24],
      "Net Profit": [1, 1, 1, 3, 4, 8, 8, 15, 120, 19, 24, 29],
      "EPS in Rs": [0.93, 0.92, 1.55, 3.23, 4.39, 7.28, 8.02, 14.60, 115.64, 18.67, 22.94, 27.83]
    },
    "Balance Sheet Highlights": {
      "Equity Capital": [4, 4, 5, 5, 10, 10, 10, 10, 10, 10, 10, 10],
      "Reserves": [13, 15, 17, 20, 19, 27, 36, 51, 171, 190, 214, 231],
      "Borrowings": [6, 8, 13, 19, 26, 29, 35, 41, 54, 90, 98, 103],
      "Other Liabilities": [12, 10, 17, 26, 40, 39, 52, 64, 105, 70, 72, 50],
      "Total Liabilities": [35, 37, 51, 71, 96, 105, 133, 166, 341, 361, 394, 394],
      "Fixed Assets": [13, 13, 13, 17, 20, 29, 43, 57, 92, 120, 139, 138],
      "CWIP": [0, 0, 0, 0, 0, 0, 0, 3, 12, 14, 0, 0],
      "Investments": [1, 1, 2, 4, 5, 5, 4, 5, 0, 0, 0, 0],
      "Other Assets": [22, 24, 37, 50, 70, 71, 86, 102, 237, 226, 255, 256],
      "Total Assets": [35, 37, 51, 71, 96, 105, 133, 166, 341, 361, 394, 394]
    },
    "Cash Flow Summaries": {
      "Cash from Operating Activity": [-1, 1, -3, 4, -1, 14, 6, 27, 61, 41, 43],
      "Cash from Investing Activity": [-3, -1, -2, -7, -6, -12, -18, -23, -63, -48, -26],
      "Cash from Financing Activity": [3, 1, 6, 5, 5, -2, 12, 1, 6, 1, -17],
      "Net Cash Flow": [-1, 1, 0, 2, -1, 0, 0, 4, 3, -6, -1]
    }
  },
  "Ratios": {
    "Growth Ratios": {
      "Compounded Sales Growth (10 Years)": "18%",
      "Compounded Sales Growth (5 Years)": "13%",
      "Compounded Sales Growth (3 Years)": "5%",
      "Compounded Sales Growth (TTM)": "30%",
      "Compounded Profit Growth (10 Years)": "41%",
      "Compounded Profit Growth (5 Years)": "31%",
      "Compounded Profit Growth (3 Years)": "25%",
      "Compounded Profit Growth (TTM)": "23%",
      "Stock Price CAGR (5 Years)": "109%",
      "Stock Price CAGR (3 Years)": "-1%",
      "Stock Price CAGR (1 Year)": "125%"
    },
    "Liquidity Ratios": {
      "Debtor Days": [41, 63, 89, 84, 98, 84, 79, 50, 55, 104, 136],
      "Inventory Days": [58, 61, 67, 71, 54, 34, 94, 38, 97, 310, 187],
      "Days Payable": [58, 40, 63, 65, 80, 52, 96, 58, 63, 117, 106],
      "Cash Conversion Cycle": [42, 85, 93, 90, 73, 67, 77, 30, 90, 297, 217],
      "Working Capital Days": [61, 81, 89, 76, 74, 61, 99, 47, 87, 209, 194]
    },
    "Profitability Ratios": {
      "ROCE %": [9, 13, 19, 19, 22, 18, 26, 98, 19, 16],
      "ROE": [30, 33, 34, 14]
    },
    "Valuation Ratios": {
      "P/E Ratio": 26.0,
      "Price to Book": "Not explicitly provided"
    }
  },
  "Peer Comparison": {
    "Peers": [
      {"Name": "Sun Pharma.Inds.", "CMP": 1808.85, "P/E": 38.73, "Mar Cap": 434003.71, "Div Yld": 0.75, "NP Qtr": 3037.33, "Qtr Profit Var": 27.86, "Sales Qtr": 13291.39, "Qtr Sales Var": 9.01, "ROCE": 17.32},
      {"Name": "Cipla", "CMP": 1472.05, "P/E": 25.81, "Mar Cap": 118884.82, "Div Yld": 0.88, "NP Qtr": 1305.01, "Qtr Profit Var": 15.18, "Sales Qtr": 7051.02, "Qtr Sales Var": 5.58, "ROCE": 22.80},
      {"Name": "Mankind Pharma", "CMP": 2805.20, "P/E": 56.07, "Mar Cap": 112393.74, "Div Yld": 0.00, "NP Qtr": 634.43, "Qtr Profit Var": 34.84, "Sales Qtr": 2529.74, "Qtr Sales Var": 11.91, "ROCE": 24.57},
      {"Name": "Dr Reddy's Labs", "CMP": 1343.65, "P/E": 21.00, "Mar Cap": 112115.62, "Div Yld": 0.60, "NP Qtr": 1341.90, "Qtr Profit Var": -15.28, "Sales Qtr": 8038.20, "Qtr Sales Var": 16.45, "ROCE": 26.53},
      {"Name": "Lupin", "CMP": 2150.70, "P/E": 37.36, "Mar Cap": 98114.41, "Div Yld": 0.37, "NP Qtr": 859.48, "Qtr Profit Var": 74.12, "Sales Qtr": 5672.73, "Qtr Sales Var": 12.59, "ROCE": 15.72},
      {"Name": "Zydus Lifesci.", "CMP": 973.50, "P/E": 22.90, "Mar Cap": 97956.88, "Div Yld": 0.31, "NP Qtr": 920.20, "Qtr Profit Var": 13.62, "Sales Qtr": 5237.00, "Qtr Sales Var": 19.87, "ROCE": 22.34},
      {"Name": "Aurobindo Pharma", "CMP": 1241.70, "P/E": 19.96, "Mar Cap": 72756.00, "Div Yld": 0.36, "NP Qtr": 816.95, "Qtr Profit Var": 8.65, "Sales Qtr": 7796.07, "Qtr Sales Var": 7.99, "ROCE": 14.10}
    ],
    "Median": {
      "CMP": 78,
      "P/E": 33.34,
      "Mar Cap": 2869.55,
      "Div Yld": 0.05,
      "NP Qtr": 17.27,
      "Qtr Profit Var": 19.36,
      "Sales Qtr": 188.19,
      "Qtr Sales Var": 9.43,
      "ROCE": 14.1
    }
  },
  "Other Insights": {
    "Pros": [
      "Company is expected to give good quarter",
      "Company has delivered good profit growth of 30.8% CAGR over last 5 years",
      "Company has a good return on equity (ROE) track record: 3 Years ROE 34.4%"
    ],
    "Cons": [
      "Though the company is reporting repeated profits, it is not paying out dividend",
      "Debtor days have increased from 98.5 to 136 days."
    ],
    "Disclaimer": "The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.",
    "Shareholding Pattern Notes": "* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards. Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes. Click on the line-items to see the names of individual entities."
  },
  "Documents": {
    "Announcements": [
      {"Date": "27 Nov", "Title": "Schedule of Analyst/Institutional Investor Meeting on December 3, 2024."},
      {"Date": "26 Nov", "Title": "Kwality receives approval for PEGylated-Asparaginase manufacturing."},
      {"Date": "6 Nov", "Title": "Approval for Leuprorelin Acetate marks entry into Europe."},
      {"Date": "6 Nov", "Title": "NEWSPAPER PUBLICATION OF RESULTS FOR QUARTER AND HALF YEAR ENDED 30-09-2024."},
      {"Date": "30 Oct", "Title": "Approved unaudited financial results for Q2 FY25."}
    ],
    "Annual Reports": ["Financial Year 2024", "Financial Year 2023", "Financial Year 2022", "Financial Year 2021", "Financial Year 2020", "Financial Year 2019", "Financial Year 2018", "Financial Year 2017", "Financial Year 2016"],
    "Credit Ratings": [
      {"Date": "22 Oct", "Agency": "icra"},
      {"Date": "29 Jul", "Agency": "crisil"},
      {"Date": "28 Aug 2023", "Agency": "icra"},
      {"Date": "31 May 2023", "Agency": "crisil"},
      {"Date": "30 Aug 2022", "Agency": "icra"},
      {"Date": "30 Mar 2022", "Agency": "crisil"}
    ],
    "Concalls": [
      {"Date": "May 2024"},
      {"Date": "May 2024"},
      {"Date": "Aug 2023"},
      {"Date": "May 2022"}
    ]
  }
}
